299 related articles for article (PubMed ID: 29708514)
1. Systemic isradipine treatment diminishes calcium-dependent mitochondrial oxidant stress.
Guzman JN; Ilijic E; Yang B; Sanchez-Padilla J; Wokosin D; Galtieri D; Kondapalli J; Schumacker PT; Surmeier DJ
J Clin Invest; 2018 Jun; 128(6):2266-2280. PubMed ID: 29708514
[TBL] [Abstract][Full Text] [Related]
2. Lower Affinity of Isradipine for L-Type Ca
Ortner NJ; Bock G; Dougalis A; Kharitonova M; Duda J; Hess S; Tuluc P; Pomberger T; Stefanova N; Pitterl F; Ciossek T; Oberacher H; Draheim HJ; Kloppenburg P; Liss B; Striessnig J
J Neurosci; 2017 Jul; 37(28):6761-6777. PubMed ID: 28592699
[TBL] [Abstract][Full Text] [Related]
3. Isradipine attenuates MPTP-induced dopamine neuron degeneration by inhibiting up-regulation of L-type calcium channels and iron accumulation in the substantia nigra of mice.
Wang QM; Xu YY; Liu S; Ma ZG
Oncotarget; 2017 Jul; 8(29):47284-47295. PubMed ID: 28521299
[TBL] [Abstract][Full Text] [Related]
4. Cav1.3 channels control D2-autoreceptor responses via NCS-1 in substantia nigra dopamine neurons.
Dragicevic E; Poetschke C; Duda J; Schlaudraff F; Lammel S; Schiemann J; Fauler M; Hetzel A; Watanabe M; Lujan R; Malenka RC; Striessnig J; Liss B
Brain; 2014 Aug; 137(Pt 8):2287-302. PubMed ID: 24934288
[TBL] [Abstract][Full Text] [Related]
5. Mitochondrial oxidant stress mediates methamphetamine neurotoxicity in substantia nigra dopaminergic neurons.
Graves SM; Schwarzschild SE; Tai RA; Chen Y; Surmeier DJ
Neurobiol Dis; 2021 Aug; 156():105409. PubMed ID: 34082123
[TBL] [Abstract][Full Text] [Related]
6. The role of calcium and mitochondrial oxidant stress in the loss of substantia nigra pars compacta dopaminergic neurons in Parkinson's disease.
Surmeier DJ; Guzman JN; Sanchez-Padilla J; Schumacker PT
Neuroscience; 2011 Dec; 198():221-31. PubMed ID: 21884755
[TBL] [Abstract][Full Text] [Related]
7. Determinants of dopaminergic neuron loss in Parkinson's disease.
Surmeier DJ
FEBS J; 2018 Oct; 285(19):3657-3668. PubMed ID: 30028088
[TBL] [Abstract][Full Text] [Related]
8. Calcium, mitochondrial dysfunction and slowing the progression of Parkinson's disease.
Surmeier DJ; Halliday GM; Simuni T
Exp Neurol; 2017 Dec; 298(Pt B):202-209. PubMed ID: 28780195
[TBL] [Abstract][Full Text] [Related]
9. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease.
Ilijic E; Guzman JN; Surmeier DJ
Neurobiol Dis; 2011 Aug; 43(2):364-71. PubMed ID: 21515375
[TBL] [Abstract][Full Text] [Related]
10. Calcium and Parkinson's disease.
Surmeier DJ; Schumacker PT; Guzman JD; Ilijic E; Yang B; Zampese E
Biochem Biophys Res Commun; 2017 Feb; 483(4):1013-1019. PubMed ID: 27590583
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of striatal dopamine release by the L-type calcium channel inhibitor isradipine co-varies with risk factors for Parkinson's.
Brimblecombe KR; Connor-Robson N; Bataille CJR; Roberts BM; Gracie C; O'Connor B; Te Water Naude R; Karthik G; Russell AJ; Wade-Martins R; Cragg SJ
Eur J Neurosci; 2024 Mar; 59(6):1242-1259. PubMed ID: 37941514
[TBL] [Abstract][Full Text] [Related]
12. The origins of oxidant stress in Parkinson's disease and therapeutic strategies.
Surmeier DJ; Guzman JN; Sanchez-Padilla J; Goldberg JA
Antioxid Redox Signal; 2011 Apr; 14(7):1289-301. PubMed ID: 20712409
[TBL] [Abstract][Full Text] [Related]
13. Mitochondrial Dysfunction Combined with High Calcium Load Leads to Impaired Antioxidant Defense Underlying the Selective Loss of Nigral Dopaminergic Neurons.
Ricke KM; Paß T; Kimoloi S; Fährmann K; Jüngst C; Schauss A; Baris OR; Aradjanski M; Trifunovic A; Eriksson Faelker TM; Bergami M; Wiesner RJ
J Neurosci; 2020 Feb; 40(9):1975-1986. PubMed ID: 32005765
[TBL] [Abstract][Full Text] [Related]
14. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1.
Guzman JN; Sanchez-Padilla J; Wokosin D; Kondapalli J; Ilijic E; Schumacker PT; Surmeier DJ
Nature; 2010 Dec; 468(7324):696-700. PubMed ID: 21068725
[TBL] [Abstract][Full Text] [Related]
15. Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout.
Giguère N; Delignat-Lavaud B; Herborg F; Voisin A; Li Y; Jacquemet V; Anand-Srivastava M; Gether U; Giros B; Trudeau LÉ
PLoS Genet; 2019 Aug; 15(8):e1008352. PubMed ID: 31449520
[TBL] [Abstract][Full Text] [Related]
16. Kir6.1/K-ATP channel on astrocytes protects against dopaminergic neurodegeneration in the MPTP mouse model of Parkinson's disease via promoting mitophagy.
Hu ZL; Sun T; Lu M; Ding JH; Du RH; Hu G
Brain Behav Immun; 2019 Oct; 81():509-522. PubMed ID: 31288070
[TBL] [Abstract][Full Text] [Related]
17. Accumulation of mitochondrial DNA deletions within dopaminergic neurons triggers neuroprotective mechanisms.
Perier C; Bender A; García-Arumí E; Melià MJ; Bové J; Laub C; Klopstock T; Elstner M; Mounsey RB; Teismann P; Prolla T; Andreu AL; Vila M
Brain; 2013 Aug; 136(Pt 8):2369-78. PubMed ID: 23884809
[TBL] [Abstract][Full Text] [Related]
18. Parkinson's Disease: Cells Succumbing to Lifelong Dopamine-Related Oxidative Stress and Other Bioenergetic Challenges.
Watanabe H; Dijkstra JM; Nagatsu T
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396687
[TBL] [Abstract][Full Text] [Related]
19. IDH2 deficiency promotes mitochondrial dysfunction and dopaminergic neurotoxicity: implications for Parkinson's disease.
Kim H; Kim SH; Cha H; Kim SR; Lee JH; Park JW
Free Radic Res; 2016 Aug; 50(8):853-60. PubMed ID: 27142242
[TBL] [Abstract][Full Text] [Related]
20. Calcium entry and α-synuclein inclusions elevate dendritic mitochondrial oxidant stress in dopaminergic neurons.
Dryanovski DI; Guzman JN; Xie Z; Galteri DJ; Volpicelli-Daley LA; Lee VM; Miller RJ; Schumacker PT; Surmeier DJ
J Neurosci; 2013 Jun; 33(24):10154-64. PubMed ID: 23761910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
